MedTrace Logo

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01168310 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2013-05-27

No results posted yet for this study

Summary

This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.

Conditions

Interventions

DRUG

Fluticasone Propionate/Formoterol Fumarate

Inhalation Suspension

DRUG

Fluticasone Propionate/Formoterol Fumarate

Inhalation Suspension

DRUG

Fluticasone Propionate/Formoterol Fumarate

Inhalation Suspension

DRUG

Fluticasone Propionate/Formoterol Fumarate

Inhalation Suspension

DRUG

Fluticasone Propionate/Formoterol Fumarate

Inhalation Suspension

DRUG

Formoterol Fumarate

Inhalation Solution

DRUG

Placebo

Inhalation Solution

Sponsors & Collaborators

  • Dey

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2010-08-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168310 on ClinicalTrials.gov